Only 200 to 400 US Fabry patients define the ADA-positive niche left open by agalsidase failure, with one competitor and one testing bottleneck.

Agalsidase beta (Fabrazyme, Sanofi Genzyme, approved 2003) remains the dominant US Fabry therapy at 60-65% market share and a 20-plus-year track record, a uniquely entrenched position since, unlike the EU and GCC markets, the US has never had a second FDA-approved ERT to compete with it directly. Migalastat (Galafold, Amicus, approved 2018), an oral chaperone for amenable GLA mutations, has reversed the historical order of preference: ERT-naive patients with a confirmed amenable mutation now start on the oral drug 50-60% of the time, up from 40-50% choosing ERT as recently as 2020.

Pegunigalsidase alfa (Elfabrio, Chiesi/Protalix, approved 2023) is the first new US ERT competitor to agalsidase in two decades, positioned narrowly for patients with high-titre anti-drug antibodies and documented suboptimal response to agalsidase beta. Only 200-400 US patients currently have the combination of high-titre ADA and documented inadequate response, persistent GL-3 elevation, eGFR decline, or progressing cardiac hypertrophy despite ERT, that defines Elfabrio's label. Identifying them requires ADA ELISA testing that is not yet routine in Fabry monitoring. A new agent's payer pathway depends on its administration route: an infused ERT bills under Medicare Part B, requiring its own HCPCS J-code, while an oral chaperone runs through Part D, requiring 18 months of PBM formulary contracting.

ADA testing infrastructure, not clinical differentiation, gates entry to this niche.

Five questions this report answers:

Q1 - What ADA and efficacy data must a new Fabry agent show to access the suboptimal-responder niche?

Q2 - How large is the ADA-positive suboptimal-responder cohort, and what infrastructure identifies it pre-approval?

Q3 - Should a new Fabry agent route through Medicare Part B or Part D?

Q4 - What must a new Fabry Disease agent prove, size, and prepare before a US launch?

Q5 - What deliverables and verification standard does every AXLRx US Fabry assessment include?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#FabryDisease #US #Medicare #RareDisease #LaunchReadiness #MarketAccess

Live report page:  https://axlrx.ai/fabry-disease/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/